92,207 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 92,207 shares of the company’s stock, valued at approximately $887,000. Raymond James Financial Inc. owned 0.06% of MiMedx Group at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of MDXG. Jane Street Group LLC lifted its stake in shares of MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after acquiring an additional 174,797 shares during the last quarter. JPMorgan Chase & Co. increased its stake in MiMedx Group by 265.4% in the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after purchasing an additional 215,995 shares during the period. Barclays PLC lifted its position in shares of MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after purchasing an additional 163,005 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of MiMedx Group by 79.9% during the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock valued at $802,000 after purchasing an additional 37,031 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after purchasing an additional 3,292 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Insider Activity at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now directly owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the sale, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock valued at $1,130,312 over the last ninety days. 1.30% of the stock is owned by company insiders.

MiMedx Group Price Performance

MDXG opened at $7.06 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $8.11 and its 200-day simple moving average is $7.94. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 12.84 and a beta of 1.74. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. On average, equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MDXG has been the subject of a number of research analyst reports. StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.